Merck and Eisai announced results from the Phase 3 LEAP-015 trial, which examined the efficacy of Keytruda plus Lenvima combined with chemotherapy as a first-line treatment for advanced HER2-negative gastroesophageal adenocarcinoma. While the combination therapy showed statistically significant improvement in progression-free survival (PFS) and objective response rate (ORR) compared to chemotherapy alone, it did not achieve the overall survival (OS) endpoint. The safety profile of the combination therapy remained consistent with previous studies.
This outcome is noteworthy due to the persistent challenges in treating gastroesophageal adenocarcinoma, a major cause of cancer-related deaths globally. While the OS endpoint was not met, the observed improvement in PFS and ORR suggests potential benefits for patient quality of life by delaying disease progression and achieving better tumor responses. This information contributes to a better understanding of combination therapy approaches for this specific cancer type, which could lead to further research and refined treatment strategies.
The LEAP-015 trial was a randomized, open-label study with dual primary endpoints of OS and PFS. The combination of Keytruda, Lenvima, and chemotherapy significantly improved PFS and ORR, a key secondary endpoint, in patients whose tumors express PD-L1 (CPS ≥1) and all randomized patients. Despite these positive results in PFS and ORR, the study did not ultimately meet its OS endpoint. Full data analysis is ongoing, and Merck and Eisai plan to present detailed findings at an upcoming medical meeting.
This trial result underscores the complex nature of gastroesophageal adenocarcinoma and the need for continued investigation into optimal treatment strategies. While the absence of an OS benefit limits the immediate clinical implications of this particular combination regimen, the improvement in PFS and ORR warrants further research to potentially identify specific patient subpopulations who may derive substantial clinical benefit from this approach. It also highlights the importance of exploring alternative treatment combinations and novel therapeutic targets in the ongoing fight against this aggressive cancer.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
